1. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma
- Author
-
Eugenia Abella, Laura Rosiñol, Mercedes Gironella, Alicia Senín, Carlos Fernández de Larrea, Alfons Soler, Cristina Motlló, Randa Ben-Azaiz, MT Cibeira, Jordi López-Pardo, Rodrigo Martino, Marta Canet, Josep Ma Martí, Jorge Sierra, Miquel Granell, Albert Oriol, Anna Barata, and Antoni Garcia-Guiñon
- Subjects
Oncology ,medicine.medical_specialty ,MEDLINE ,Return to work ,Transplantation, Autologous ,Return to Work ,Autologous stem-cell transplantation ,Quality of life ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Multiple myeloma ,Transplantation ,Bortezomib ,business.industry ,Hematopoietic Stem Cell Transplantation ,Cancer ,Hematology ,medicine.disease ,Cohort ,Quality of Life ,Multiple Myeloma ,business ,Stem Cell Transplantation ,medicine.drug - Abstract
Return to work (RTW) is a marker of functional recovery in cancer patients, with quality of life, financial and social implications. We investigated frequency and factors associated with RTW in a cohort of patients younger than 66 years, with newly diagnosed multiple myeloma (MM), uniformly treated with a bortezomib-based induction followed by autologous stem cell transplantation (ASCT). Socio-economic and working status data were collected by a self-administered questionnaire. One hundred and eighty-six patients entered the study. Of whom, 145 (78%) where employed at diagnosis, which was more frequent in younger (median 55 vs. 60 years, p < 0.001), men (59.3% vs. 34.2%, p = 0.004), and with college studies (44.8% vs. 24.4%, p = 0.008). Forty-three (30%) of the 145 patients who had a job at diagnosis, RTW after ASCT in a median of 5 (range 1-27) months. Factors independently associated with RTW were having three or more children (HR 2.87, 95% CI 1.33-6.18), college studies (HR 2.78, 95% CI 1.21-6.41), and a family income >40 × 10(3)€/year (HR 2.31, 95% CI 1.12-4.78). In conclusion, the frequency of RTW herein reported in MM patients seems lower than reported in other malignancies. The risk factors observed may guide the design RTW programs.
- Published
- 2021